2. Laupheimer Zelltage Attracts Top Scientists to Discuss Recent Advances in Biomanufacturing
Rentschler has seen participation at this conference nearly triple since inaugural event in 2010
The symposium program consisted of three sessions focusing on New Targets for Animal Cell Technology', 'The Efficient Process' and 'Cutting-Edge Technologies'. The lectures included a wide range of topics such as predicting cell line productivity, the advantage of pre-developed producer cells, key components of chemically defined cell culture media, and novel disposable and process intensification technologies. Thus, these presentations helped forge a link between cell line development and production.
"Contract manufacturers are pushed towards continuously improving processes and the two-day event was full of inspiring lectures and discussions on new strategies and technologies to enhance quality, efficiency and process robustness," said Prof. Roland Wagner, Senior Vice President Development at Rentschler. "Besides process optimization, there is a clearly visible trend towards flexible multiproduct manufacturing facilities to reduce the cost of goods, significantly lower initial capital investments, and increase plant capacity."
The Laupheimer Zelltage conferences on industrial cell culture technology are carried out in a biennial rhythm. The next conference in June 2014 will be on Advanced Therapy Medicinal Products and is entitled "Processes for ATMPs'.
Rentschler Biotechnologie GmbH
Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1,000 and 2,500 liters, allowing the production of material for clinical trials (phases I to III) and for market supply and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.
Press releases you might also be interested in
Weitere Informationen zum Thema "Biotechnik":
Steigende Cyber-Angriffe durch Künstliche Intelligenz
Avast, Hersteller von digitalen Sicherheitsprodukten, hat den Sicherheitsreport für 2018 vorgestellt. Daraus geht hervor, dass in diesem Jahr verstärkt eine Kombination aus neuen und traditionellen Sicherheitsbedrohungen auftreten wird, darunter auch erste Angriffe, die auf Künstlicher Intelligenz basieren.Weiterlesen